Kamali Alireza, Sanatkar Amir, Sharifi Mehrzad, Moshir Esmaeil
Department of Anesthesiology, Arak University of Medical Sciences, Arak, Iran.
Department of Surgery, Arak University of Medical Sciences, Arak, Iran.
Interv Med Appl Sci. 2017 Jun;9(2):51-55. doi: 10.1556/1646.9.2017.2.11.
Atrial fibrillation (AF) is the most common arrhythmia affecting patients in open heart ICU after coronary artery bypass grafting (CABG). Most cardiac surgery textbooks recommend beta blockers as the drug of choice for treating such a condition while many experienced physicians and a number of anesthesiology references offer amiodarone as the drug of choice. Therefore, because of insufficient evidence and the aforementioned controversy, we decided to conduct a study evaluating these two antiarrhythmic medicines.
This is a double-blind, randomized, clinical trial performed on patients admitted for CABG at Amir al Momenin hospital in Arak province, Iran, who developed new onset AF after surgery. Based on the type of medication used, these patients were randomly divided into two groups: amiodarone (A) group and metoprolol (M) group. Each group consisted of 73 cases. All data were analyzed via SPSS 19.
Among the results achieved in this study, amiodarone was successful in treating AF in 55 patients (73%), while metoprolol achieved normal rhythm in treating AF in 69 patients (92%). With a -value of 0.04, it seems that metoprolol is more effective in treating AF.
Metoprolol seems to be a most efficacious medication for post-CABG AF (-value = 0.004).
心房颤动(AF)是冠状动脉旁路移植术(CABG)后心脏重症监护病房(ICU)中影响患者的最常见心律失常。大多数心脏外科教科书推荐β受体阻滞剂作为治疗此类病症的首选药物,而许多经验丰富的医生和一些麻醉学参考文献则推荐胺碘酮作为首选药物。因此,由于证据不足以及上述争议,我们决定开展一项研究来评估这两种抗心律失常药物。
这是一项双盲、随机临床试验,对伊朗阿拉克省阿米尔·穆明医院因CABG入院且术后出现新发房颤的患者进行。根据所用药物类型,这些患者被随机分为两组:胺碘酮(A)组和美托洛尔(M)组。每组有73例病例。所有数据均通过SPSS 19进行分析。
在本研究取得的结果中,胺碘酮成功治疗了55例房颤患者(73%),而美托洛尔使69例房颤患者恢复正常心律(92%)。P值为0.04,美托洛尔似乎在治疗房颤方面更有效。
美托洛尔似乎是治疗CABG术后房颤最有效的药物(P值 = 0.004)。